Design, synthesis, antifungal activity, and ADME prediction of functional analogues of terbinafine
暂无分享,去创建一个
Vithal M. Kulkarni | Prashant S. Kharkar | V. Kulkarni | P. Kharkar | Meenakshi N. Deodhar | M. Deodhar
[1] K. Subramanian. truPK – human pharmacokinetic models for quantitative ADME prediction , 2005, Expert opinion on drug metabolism & toxicology.
[2] P. Nussbaumer,et al. Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine. , 1993, Journal of medicinal chemistry.
[3] P. Trown,et al. Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice , 1985, Antimicrobial Agents and Chemotherapy.
[4] P. Nussbaumer,et al. Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment. , 1993, Journal of medicinal chemistry.
[5] F. Odds. Resistance of yeasts to azole-derivative antifungals. , 1993, The Journal of antimicrobial chemotherapy.
[6] N. Ryder. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent , 1985, Antimicrobial Agents and Chemotherapy.
[7] R. Diamond,et al. The growing problem of mycoses in patients infected with the human immunodeficiency virus. , 1991, Reviews of infectious diseases.
[8] Panos Macheras,et al. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. , 2002, European Journal of Pharmaceutical Sciences.
[9] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[10] C. Hitchcock. Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals. , 1991, Biochemical Society transactions.
[11] D. Denning,et al. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. , 1991, The Journal of antimicrobial chemotherapy.
[12] M. Richardson. Opportunistic and pathogenic fungi. , 1991, The Journal of antimicrobial chemotherapy.
[13] N S Ryder,et al. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. , 1984, Science.
[14] P. Nussbaumer,et al. Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics. , 1991, Journal of medicinal chemistry.
[15] G. Daum,et al. Squalene and ergosterol biosynthesis in fungi treated with naftifine, a new antimycotic agent , 1982 .
[16] James J. P. Stewart,et al. MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..
[17] J. Adler,et al. The functional importance of structural features of ergosterol in yeast. , 1978, The Journal of biological chemistry.
[18] M. Akova,et al. Emergence ofCandida krusei infections after therapy of oropharyngeal candidiasis with fluconazole , 1991, European Journal of Clinical Microbiology and Infectious Diseases.
[19] P. Nussbaumer,et al. Synthesis and structure-activity relationships of the novel homopropargylamine antimycotics. , 1994, Journal of medicinal chemistry.
[20] M. Nettleman,et al. Secular Trends in the Epidemiology of Nosocomial Fungal Infections at a Teaching Hospital in Taiwan, 1981 to 1993 , 1997, Infection Control & Hospital Epidemiology.
[21] Johnson,et al. Predicting human safety: screening and computational approaches. , 2000, Drug discovery today.
[22] P. Hawkey,et al. Medical bacteriology : a practical approach , 1989 .
[23] C. Beck-Sague,et al. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.
[24] P. Nussbaumer,et al. Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function. , 1995, Journal of medicinal chemistry.
[25] C. Sonnenschein,et al. Failure of fluconazole therapy inCandida krusei fungemia , 1991, European Journal of Clinical Microbiology and Infectious Diseases.
[26] Pickett,et al. Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.
[27] R. Cramer,et al. Validation of the general purpose tripos 5.2 force field , 1989 .
[28] V. Kulkarni,et al. Comparative molecular field analysis of fungal squalene epoxidase inhibitors. , 1999, Journal of medicinal chemistry.